Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers

European Journal of Cancer

Volumn 34, Issue 11, 1998, Pages 1683-1686

  Osin, P ^a   Gusterson, B A ^a   Philp, E ^a   Waller, J ^a   Bartek, J ^b   Peto, J ^a   Crook, T ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Anti oestrogen; Breast; Cancer; Familial

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN D1; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN PS2;

ADULT; ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; HORMONE DEPENDENCE; HORMONE RESISTANCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; BRCA2 PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYCLIN D1; FEMALE; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM PROTEINS; PROTEINS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0032188956     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00248-2     Document Type: Article

References (19)

1. 1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene. Science 1994, 266, 66-71.
2. 2. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1996, 378, 789-792.
3. 3. Gayther SA, Warren W, Mazoyer S, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 1995, 11(4), 428-433.
4. 4. Gayther SA, Mangion J, Russell P, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997, 15(1), 103-105.
5. 5. Breast Cancer Linkage Consortium. The pathology of familial breast cancer: differences between breast cancer in carriers of BRCA1 or BRCA2 mutations and sporadic breast cancer. Lancet 1997, 349, 1505-1510.
6. 6. Crook T, Crossland S, Crompton MR, Osin P, Gusterson BA. P53 mutation in BRCA1-associated familial breast cancer. Lancet 1997, 350, 638-639.
7. 7. Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: pathobiology, prognosis and BRCA1 and BRCA2 gene linkage. Cancer 1996, 77, 697-709.
8. 8. Eisenger F, Stoppa-Lyonnet D, Longy M, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996, 56, 471-474.
9. 9. Jóhannsson OT, Idvall I, Anderson C, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997, 33(3), 362-371.
10. 10. Johnston SRD, Saccani-Jotti G, Smith IE, et al. Changes in oestrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995, 55, 3331-3338.
11. 11. Johnston SRD, Lu B, Dowsett M, et al. Comparison of oestrogen receptor DNA-binding in untreated and acquired anti-oestrogen-resistant human breast tumours. Cancer Res 1997, 57, 3723-3727.
12. 12. Detre S, King N, Salter J, MacLennan K, McKinna JA, Dowsett M. Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer. J Clin Pathol 1994, 47, 240-244.
13. 13. Sutherland RL, Watts CKW, Musgrove EA. Cell cycle control by steroid hormones in breast cancer: implications for endocrine resistance. Endocrine-Related Cancer 1995, 2(1), 87-96.
14. 14. Watts CKW, Brady A, Sarcevic B, de Fazio A, Musgrove EA, Sutherland RL. Antioestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 1995, 9(12), 1804-1813.
15. 15. Zwijsen RML, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJAM. CDK-independent activation of oestrogen receptor by cyclin D1. Cell 1997, 88, 405-415.
16. 16. Bartkova J, Lukas J, Muller H, Strauss M, Gusterson BA, Bartek J. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res 1995, 55, 949-956.
17. 17. Detre S, Saccani Jotti G, Dowsett MA. "Quick score" method for immunohistochemical semiquantitative validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995, 48, 876-878.
18. 18. Gillett C, Smith P, Gregory W, et al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer (Pred Oncol) 1996, 69, 92-99.
19. 19. Nielsen NH, Emdin SO, Landberg G. Deregulation of G1 cyclins and pRb alterations in oestrogen receptor negative breast cancer with poor prognosis. Proc AACR 1996, 37, 28.